Loading...
XNASAPTO
Market cap14mUSD
Dec 23, Last price  
0.25USD
1D
-10.82%
1Q
-37.96%
Jan 2017
-98.81%
Name

Aptose Biosciences Inc

Chart & Performance

D1W1MN
XNAS:APTO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.86%
Rev. gr., 5y
%
Revenues
0k
024,000100,02343,023168,807124,15600000000000000
Net income
-51m
L+24.73%
000005,052,5050000000-11,661,000-28,868,000-25,697,000-54,708,000-65,261,000-41,053,000-51,207,000
CFO
-45m
L+37.96%
0000000000000-10,291,000-23,207,000-21,558,000-33,891,000-43,304,000-32,322,000-44,590,000
Earnings
Mar 24, 2025

Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
URL
https://aptose.com/
IPO date
Jun 04, 1993
Employees
35
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
52,831
43,028
65,926
Unusual Expense (Income)
NOPBT
(52,831)
(43,028)
(65,926)
NOPBT Margin
Operating Taxes
(770)
(93)
Tax Rate
NOPAT
(52,831)
(42,258)
(65,833)
Net income
(51,207)
24.73%
(41,053)
-37.09%
(65,261)
19.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,881
101
36
BB yield
-40.10%
-0.19%
-0.03%
Debt
Debt current
394
301
459
Long-term debt
1,636
2,305
689
Deferred revenue
Other long-term liabilities
Net debt
(7,222)
(44,353)
(77,980)
Cash flow
Cash from operating activities
(44,590)
(32,322)
(43,304)
CAPEX
(29)
(24)
(212)
Cash from investing activities
9,960
30,066
(35,208)
Cash from financing activities
6,910
116
226
FCF
(49,437)
(42,978)
(65,435)
Balance
Cash
9,252
46,959
79,128
Long term investments
Excess cash
9,252
46,959
79,128
Stockholders' equity
(75,047)
(31,128)
10,563
Invested Capital
73,161
70,172
64,247
ROIC
ROCE
2,801.20%
EV
Common stock shares outstanding
6,755
6,151
5,939
Price
2.54
-70.80%
8.70
-57.04%
20.25
-69.18%
Market cap
17,158
-67.94%
53,515
-55.50%
120,266
-66.45%
EV
9,936
9,162
42,286
EBITDA
(52,365)
(42,500)
(65,304)
EV/EBITDA
Interest
770
Interest/NOPBT